Nasdaq - Delayed Quote USD

Fidelity Disruptive Medicine Lylty 2 (FRXMX)

11.61 -0.04 (-0.34%)
At close: January 23 at 8:00 PM EST
Loading Chart for FRXMX
DELL
  • Previous Close 11.65
  • YTD Return 7.08%
  • Expense Ratio 1.00%
  • Category Health
  • Last Cap Gain -22.00
  • Morningstar Rating
  • Morningstar Risk Rating Above Average
  • Sustainability Rating
  • Net Assets 43.22M
  • Beta (5Y Monthly) 0.79
  • Yield 0.00%
  • 5y Average Return --
  • Holdings Turnover 47.00%
  • Last Dividend --
  • Inception Date Apr 16, 2020

Normally the fund invests at least 80% of assets in securities of disruptive medicine companies. Normally it invests primarily in equity securities. Companies within the disruptive medicine theme include but are not limited to those companies that, in the Adviser's opinion, are engaged in robotic surgery, gene therapy, genomics, rare diseases, medical devices and equipment, immunotherapy, technology-based health care platforms, and consumer wellness. The fund is non-diversified.

Fidelity Investments

Fund Family

Health

Fund Category

43.22M

Net Assets

2020-04-16

Inception Date

Performance Overview: FRXMX

Trailing returns as of 5/11/2023. Category is Health.

YTD Return

FRXMX
7.08%
Category
7.95%
 

1-Year Return

FRXMX
26.36%
Category
30.16%
 

3-Year Return

FRXMX
2.80%
Category
16.10%
 

5-Year Return

FRXMX
0.00%
Category
15.71%
 

Holdings: FRXMX

Top 10 Holdings (36.22% of Total Assets)

SymbolCompany% Assets
BSX
Boston Scientific Corporation 4.41%
HUM
Humana Inc. 3.99%
UNH
UnitedHealth Group Incorporated 3.94%
PODD
Insulet Corporation 3.83%
VRTX
Vertex Pharmaceuticals Incorporated 3.72%
MASI
Masimo Corporation 3.33%
RPRX
Royalty Pharma plc 3.29%
PEN
Penumbra, Inc. 3.29%
DHR
Danaher Corporation 3.22%
LLY
Eli Lilly and Company 3.19%

Sector Weightings

SectorFRXMX
Healthcare   100.00%
Real Estate   0.00%
Technology   0.00%
Utilities   0.00%
Industrials   0.00%
Energy   0.00%

Recent News: FRXMX

Research Reports: FRXMX

Top Mutual Funds